Code | 43536 | ||||||||||
MA number | EU/1/07/391/004 | ||||||||||
Product Form: | cps dur 21x25 mg (blis. PCTFE/PVC/Al) | ||||||||||
MA Status: | E - Valid centralised marketing authorisation | ||||||||||
Type of procedure: | EU | ||||||||||
MAH, country: | Bristol-Myers Squibb Pharma EEIG , Ireland | ||||||||||
Therapeutic Class: | 59 - IMMUNOPRAEPARATA | ||||||||||
ATC: |
|
||||||||||
Shelf life: | 36 | ||||||||||
Container: | blister PCTFE/PVC/Al | ||||||||||
Route of admin.: | Oral use |
Prescription Status: | Medicinal product subject to restricted medical prescription. |
Legal basis: | Article 8(3) application |
MA issued: | 14.06.2007 |
SmPC + PL: | European Medicines Agency's database |
Dokument: | DHPC Revlimid 7 11 2016.pdf |
Dokument: | DHPC 2 Revlimid_SUKL_8 4 2011.pdf |
Dokument: | DHPC Revlimid 19 10 2011.pdf |
Dokument: | DHPC Revlimid_SUKL_clean.doc |
Safety feature | Yes |
Data update: | 11.06.2019 |